HONG KONG, Jan. 1 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the underwriters of its recent public offering of common stock have exercised the remaining portion of their over-allotment option, which will result in the issuance of an additional 181,000 ordinary shares. The option was granted in connection with the public offering of 3,305,786 ordinary shares at a public offering price of $6.05 per share, which closed on November 24, 2009. The closing of the full over-allotment issuance of 495,867 ordinary shares is scheduled for Tuesday, January 5, 2010 and will bring the total gross proceeds of the public offering to $23 million. China Cord Blood Corporation intends to use the net proceeds from the offering for the expansion into new geographical markets, including applications for new licenses and acquisitions and investments, and for the construction and upgrading of facilities in existing geographical markets.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering has been conducted solely by means of a prospectus supplement and accompanying prospectus relating to the offering of common stock can be obtained by contacting Rodman & Renshaw, LLC, 1251 Avenue of the Americas, New York, NY 10020, or by calling 212-430-1710. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission.
Forward-looking Statements
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in the People's Republic of China, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
CONTACT: Ms. Joeling Law of China Cord Blood Corporation, Phone:
+852-3605-8180, Email: ir@chinacordbloodcorp.com; or in the United States:
Ashley M. Ammon or Christine Duan of ICR, Inc., Phone: +1-646-277-1227; or
in China: Wei-Jung Yang, Phone: +86-10-6599-7968
Web site: http://www.chinacordbloodcorp.com/
